Fortrea Holdings Inc. (FTRE)
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Sector: Services-Medical Laboratories
Industry: Biotechnology
Fortrea Holdings Inc.
1-25 of 338 filings
Recent SEC filings with analysis
- 10-QFortrea returned to slight profitability in Q3 2026 with net income of $0.6M ($0.01 EPS) versus a $15.9M loss a year earlier, though revenue slipped 1.4% to…
- 8-KFortrea reported Q3 2026 revenue of $691.5 million, down slightly from $701.3 million a year ago, but swung to GAAP net income of $0.6 million ($0.01 diluted…
- 8-KFortrea Holdings appointed Carrie Russell as Chief Accounting Officer effective October 5, 2026, converting her interim role into the permanent position.